Cisplatin
Cisplatin (cisplatin) is a small molecule pharmaceutical. Cisplatin was first approved as Cisplatin on 1982-01-01. It is used to treat amelanotic melanoma, astrocytoma, breast neoplasms, cystic mesothelioma, and esophageal neoplasms amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cisplatin (discontinued: Cisplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cisplatin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CISPLATIN | HQ Specialty Pharma | N-018057 RX | 1982-01-01 | 2 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cisplatin | ANDA | 2025-11-19 |
Indications
FDA
EMA
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9060 | Injection, cisplatin, powder or solution, 10 mg |
Clinical
Clinical Trials
5012 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine cervical neoplasms | D002583 | — | — | — | 2 | 2 | — | — | 3 |
| Nasopharyngeal carcinoma | D000077274 | — | — | — | 1 | 2 | — | — | 2 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | 1 | 2 | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 3 | 5 | — | — | — | 5 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
| Malignant mesothelioma | D000086002 | — | — | 1 | 1 | — | — | — | 1 |
| Mesothelioma | D008654 | — | C45 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cisplatin |
| INN | cisplatin |
| Description | Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | antineoplastics (platinum derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 15663-27-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL11359 |
| ChEBI ID | — |
| PubChem CID | 5702198 |
| DrugBank | DB00515 |
| UNII ID | Q20Q21Q62J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 157,332 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cisplatin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
73,721 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use